Large-scale testing (Phase 3)Looking for participantsNCT06345729
What this trial is testing
Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 600